Innovative Air Monitoring Services, Launches, Partnerships, Accreditations, and Top Workplace Recognitions - Analyst Notes on PerkinElmer, Agilent, Centene, Waters and Medivation

NEW YORK, June 19, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding PerkinElmer Inc. (NYSE: PKI), Agilent Technologies Inc. (NYSE: A), Centene Corp. (NYSE: CNC), Waters Corp. (NYSE: WAT) and Medivation, Inc. (NASDAQ: MDVN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3886-100free.

PerkinElmer Inc. Analyst Notes
On June 9, 2014, PerkinElmer Inc. (PerkinElmer) announced the launch of Elm - its innovative air monitoring service. According to the Company, Elm provides local air quality analysis for individuals, smart cities and sustainable communities by enabling the understanding of air quality detail through the availability of useful data online and on mobile devices. The Company stated that the Elm network contains devices with multiple air monitoring sensors, with units that are placed outdoors including industrial areas, neighborhoods, parks and schools where individuals can benefit from real-time air quality information. PerkinElmer's President for Environmental Health, Jon DiVincenzo commented, "We are very excited to introduce our innovative Elm solution which leverages PerkinElmer's detection capabilities and expertise in environmental monitoring to transform how air quality is understood and explained. Using a novel approach, the Elm network is designed to create better awareness, empowering all of us to connect our understanding about the quality of our environment with its long-term impact on our health - helping cities and their populations make smarter, more informed decisions." The full analyst notes on PerkinElmer are available to download free of charge at:

http://www.analystsreview.com/Jun-19-2014/PKI/report.pdf

Agilent Technologies Inc. Analyst Notes
On June 16, 2014, Agilent Technologies Inc. (Agilent) announced that it has partnered with Cerno Bioscience to distribute Cerno Bioscience's MassWorks calibration and analysis software with all Agilent GC/MSD systems in an effort to make the MassWorks software broadly available to more users. The Company stated that this novel calibration technology increases the mass accuracy of Agilent's single-quadrupole GC/MSD to enable unknown compound identification. Agilent's GC and GC/MS Solutions Division Vice President and General Manager, Monty Benefiel commented, "Making Cerno MassWorks directly available to GC/MSD users through Agilent channels opens the qualitative power of accurate mass information to scan MS users worldwide. Customers can now benefit from this new capability at an attractive incremental cost when purchasing GC/MSD systems." The full analyst notes on Agilent are available to download free of charge at:

http://www.analystsreview.com/Jun-19-2014/A/report.pdf

Centene Corp. Analyst Notes
On June 16, 2014, Centene Corp. announced that Coordinated Care- it's wholly owned Washington based subsidiary, has received accreditation from the National Committee for Quality Assurance (NCQA) for both its Medicaid and Exchange HMO plans. Coordinated Care's President and CEO Jay Fathi, M.D. commented, "The Coordinated Care team is proud to receive this NCQA Accreditation. It confirms our commitment to quality improvement and dedication to our purpose of transforming the health of the community, one person at a time. This Accreditation speaks to our strengths, including collaboration, commitment to comprehensive member care, innovative outreach to members and dedication to constantly evaluating ourselves and looking for opportunities to enhance the way we impact the lives of those we serve." The full analyst notes on Centene are available to download free of charge at:

http://www.analystsreview.com/Jun-19-2014/CNC/report.pdf

Waters Corp. Analyst Notes
On June 16, 2014, Waters Corp. (Waters) announced the launch of two new Xevo® mass spectrometers, and the expansion of ionKey/MS System at the 62nd conference of the American Society of Mass Spectrometry. According to the Company, these new products will take benchtop quantitative and qualitative applications to new levels. Mass Spectrometry Operations, Waters' Division Vice President, Brian Smith commented, "The technology embodied in the Xevo G2-XS benefits laboratory analysis in a number of ways. Most importantly, laboratories now have a dependable option for performing qualitative and quantitative experiments for both known and unknown analytes with a benchtop QTof instrument." On the same day, Waters also announced the launch of Progenesis® QI for proteomics Version 2.0, which is the latest advance in proteomics data analysis software. The full analyst notes on Waters are available to download free of charge at:

http://www.analystsreview.com/Jun-19-2014/WAT/report.pdf

Medivation, Inc. Analyst Notes
On June 16, 2014, Medivation, Inc. (Medivation) announced that the Company has been named among the top mid-sized companies in the San Francisco Bay Area News Group's annual Top Workplaces competition for the second consecutive year. Medivation informed that it stood 17 among other companies included in the survey, and is the only life science company in that category. Medivation Founder, President and CEO, David Hung, M.D. commented, "I am proud to say that this spirit is evident in our daily interactions as colleagues, the game-changing success we've achieved to date, and the evident determination of everyone on the team to pursue the significant opportunities that still lie ahead. I can't think of a better, more exciting place to work and I am deeply gratified that our employees feel the same way." The full analyst notes on Medivation are available to download free of charge at:

http://www.analystsreview.com/Jun-19-2014/MDVN/report.pdf

About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.

===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.analystsreview.com/

SOURCE Analysts Review